Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months
A cohort study found that pre-radical prostatectomy levels greater than 20 ng/mL were associated with increased all-cause mortality risk and prostate cancer-specific mortality risk.
Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer
The phase 3 ARTISTRY-7 trial has been halted and nemvaleukin is no longer being developed for the treatment of patients with platinum-resistant ovarian cancer.
Hospital Length of Stay After NSCLC Surgery Higher With Wildfire Exposure
A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
FDA Approves Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors
Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.
Discussing the Applicability of ACRO Findings to Radiation Oncology Practice
ACRO presentations may enable community practices to utilize cutting-edge radiation advances to deliver optimal treatment to patients.
Ensartinib Yields “Promising” Efficacy in Pretrated METex14–positive NSCLC
In the phase 2 EMBRACE trial, ensartinib demonstrated an ORR of 53.3%, a DCR of 86.7%, and a tumor shrinkage rate of 33.3% in patients with METex14-positive NSCLC.
ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
Antibody-drug conjugates like Rina-S may be able to salvage some of the responses that are often lost in the later lines of treatment, according to Elizabeth Lee, MD.
Modakafusp Alfa Exhibits Antitumor Activity, Immune Activation in Myeloma
Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.
Cretostimogene Grenadenorepvec Yields Sustained Antitumor Activity in NMIBC
No grade 3 or higher treatment-related adverse effects or deaths were reported among those with non-muscle invasive bladder cancer in the BOND-003 trial.
HSCT Recipients Show Sustained Health Challenges Following Transplant
Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.
Women in Rural Regions Experience Greater Cervical Cancer Incidence/Mortality
Increased incidence and mortality rates for cervical cancer among rural women in the US may result from barriers to access to care.
Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
“There is, potentially, a role for Rina-S or other novel ADCs targeting different epitopes on the cancer cell surface,” Elizabeth Lee, MD, stated.
Selpercatinib Demonstrates Durable Responses in RET Fusion–Positive NSCLC
In patients who were pretreated and treatment naïve with RET fusion-positive NSCLC, selpercatinib yielded an ORR of 61.5% and 82.6%, respectively.
Mipletamig/SOC Achieved Complete Remission Rates in Front-Line AML
Results from the RAINIER trial showed that mipletamig, venetoclax, and azacitidine achieved a complete remission rate of 90% in patients with AML.
NeuroSAFE Improves Erectile Function, Urinary Continence in Prostate Cancer
The adverse effect profile was similar among patients with prostate cancer using NeuroSAFE-assisted RARP vs standard RARP.
Crucial Answers on Long-Term Physical Health Effects From Breast Cancer Treatments
Clara Bodelon, PhD, MS, discussed her recently published study which found that the greatest physical health declines in patients who survived breast cancer stemmed from chemotherapy.
Considering Dosing and AE Management Strategies With Tarlatamab in SCLC
Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.
Various Mechanisms May Inform Nivolumab Use in Gastroesophageal Cancer
Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.
Daratumumab Continues to Show Activity in Smoldering Multiple Myeloma
Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.
Radiation Oncologist Strives to Improve the Patient Experience
“As a field, we’re trying to push hard to make [radiation] patient-centered, and because of that, the field is the future of the field is pretty bright,” James B. Yu, MD, MHS, FASTRO, stated.
Radiation Therapy Does Not Improve Survival in Gastric/GEJ Cancers
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Reirradiation of the Prostate May Become Feasible Treatment Option
James B. Yu, MD, MHS, FASTRO, believes that 2 of the most intriguing and growing areas of radiation oncology are reirradiation of the prostate and bladder chemoradiation.
Atezolizumab After Chemoradiotherapy Elicits Promising Responses in ESCC
In the phase 2 EPOCI1802 trial, atezolizumab monotherapy elicited a cCR rate of 42.1%, an ORR of 65.8%, and a 12-month OS rate of 65.8% in advanced ESCC.
Durvalumab Plus FLOT May Not Significantly Increase AEs in Gastric Cancer
Most adverse effects observed in combination therapies for gastric cancers are associated with chemotherapy, according to Yelena Y. Janjigian, MD.
Atezolizumab/Chemotherapy May Show Meaningful Activity in Thymic Carcinoma
Phase 2 data may support atezolizumab plus chemotherapy as a treatment option in advanced or recurrent thymic carcinoma.
Tamoxifen Shows No Notable Long-Term Physical Health Decline in BC Survivors
“The idea is that the patients are informed of the long-term consequences [of the treatments] so they can have some [input in] decision making,” Clara Bodelon, PhD, MS, stated.
FDA Issues Second Camrelizumab/Rivoceranib CRL in Hepatocellular Carcinoma
The complete response letter for camrelizumab/rivoceranib for patients with advanced HCC did not specify what deficiencies regulators found.
FDA Approves PET Imaging Agent for Prostate Cancer
The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.
Elotuzumab Plus PVd Displays Efficacy in Relapsed/Refractory Multiple Myeloma
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.
Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer
Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.
